MoonLake Stock Jumps on Imminent Late-Stage Trial Catalysts

MoonLake Immunotherapeutics' (MLTX) stock rose by 2.5% as investors position for late-stage trial catalysts, particularly in hidradenitis suppurativa (HS). The company's lead drug sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on HS.

MoonLake ran two large trials involving about 838 patients with moderate-to-severe HS. While one trial met its main goal, the other narrowly missed it due to an unusually high placebo response rate. Full 52-week results from both trials are expected in the second quarter and will show how well the benefits hold up over a full year.

Additionally, MoonLake has a smaller late-stage study in adolescents with HS. Data from this trial is intended to support a label that includes patients as young as 12. After a positive meeting with the FDA in April 2026, MoonLake plans to submit its application for approval at the end of September 2026.

Merck has been considered a potential acquirer for MLTX after reports surfaced in June 2025 that the company approached MoonLake with a buyout offer. Analysts covering MLTX have an average price target of $27.62, representing a potential upside of about 46% from its last close.

Despite retail traders' optimism for the upcoming data and potential merger talks, some users on Stocktwits voiced caution, highlighting the risk of an unusually high placebo response rate in one of the trials.